TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prophylaxis of Thromboembolism in Critically Ill Patients Using Combined Intermittent Pneumatic Compression(IPC) and Pharmacologic Prophylaxis Versus Pharmacologic Prophylaxis Alone: A Multicenter Randomized Controlled Trial
Brief Summary: Patients admitted to the intensive care unit are at high risk of developing clots in the veins of the lower extremities. The objective of this study is to examine whether the use of a device that provides intermittent compression to the legs in addition to the use of low-dose blood thinners, provides an additional protection when compared to the use of blood thinners alone. Patients who are admitted to the intensive care unit are receiving low-dose blood thinners to prevent clots are candidates for this study. Patients who are enrolled will continue to receive blood thinners but some will additionally receive the leg compression. The additional use of leg compression may provide protection from clots. The main side effect is possible skin abrasions but this is usually mild. The study is sponsored by King Abdullah International Medical Research Center(KAIMRC) and King Abdulaziz City for Science and Technology(KACST) and will be conducted in several hospitals in Saudi Arabia, Canada, Australia, Brazil and possibly other countries. The study started July 2014 and is to continue for 4 years.


Options:
A: Arm Label: High Risk for VTE recieving dalteparin; Type: EXPERIMENTAL; Interventions: Drug: dalteparin injection | Arm Label: High Risk for VTE No therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Risk for VTE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: dalteparin injection; Assigned to Arm(s): High Risk for VTE recieving dalteparin
B: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for semuloparin) | Intervention Type: DRUG; Name: Semuloparin sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Placebo (for semuloparin); Assigned to Arm(s): Placebo
C: Arm Label: PEG-asparaginase 6 weeks intervals; Type: EXPERIMENTAL; Interventions: Drug: PEG Asparaginase at six weeks interval | Arm Label: PEG-Asparaginase 2 weeks intervals; Type: ACTIVE_COMPARATOR; Interventions: Drug: PEG Asparaginase at two weeks interval | Intervention Type: DRUG; Name: PEG Asparaginase at six weeks interval; Assigned to Arm(s): PEG-asparaginase 6 weeks intervals | Intervention Type: DRUG; Name: PEG Asparaginase at two weeks interval; Assigned to Arm(s): PEG-Asparaginase 2 weeks intervals
D: Arm Label: Intermittent Pneumatic Compression(IPC); Type: EXPERIMENTAL; Interventions: Device: pneumatic compression | Arm Label: No Intermittent Pneumatic Compression; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: pneumatic compression; Assigned to Arm(s): Intermittent Pneumatic Compression(IPC)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prophylaxis of Thromboembolism in Critically Ill Patients Using Combined Intermittent Pneumatic Compression(IPC) and Pharmacologic Prophylaxis Versus Pharmacologic Prophylaxis Alone: A Multicenter Randomized Controlled Trial
Brief Summary: Patients admitted to the intensive care unit are at high risk of developing clots in the veins of the lower extremities. The objective of this study is to examine whether the use of a device that provides intermittent compression to the legs in addition to the use of low-dose blood thinners, provides an additional protection when compared to the use of blood thinners alone. Patients who are admitted to the intensive care unit are receiving low-dose blood thinners to prevent clots are candidates for this study. Patients who are enrolled will continue to receive blood thinners but some will additionally receive the leg compression. The additional use of leg compression may provide protection from clots. The main side effect is possible skin abrasions but this is usually mild. The study is sponsored by King Abdullah International Medical Research Center(KAIMRC) and King Abdulaziz City for Science and Technology(KACST) and will be conducted in several hospitals in Saudi Arabia, Canada, Australia, Brazil and possibly other countries. The study started July 2014 and is to continue for 4 years.


Options:
A: Arm Label: intermittent pneumatic compression; Type: EXPERIMENTAL; Interventions: Drug: low molecular weight heparin | Intervention Type: DRUG; Name: low molecular weight heparin; Assigned to Arm(s): intermittent pneumatic compression
B: Arm Label: Intermittent Pneumatic Compression(IPC); Type: EXPERIMENTAL; Interventions: Device: pneumatic compression | Arm Label: No Intermittent Pneumatic Compression; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: pneumatic compression; Assigned to Arm(s): Intermittent Pneumatic Compression(IPC)
C: Arm Label: Experimental group (SCD + GCS + LMWH); Type: EXPERIMENTAL; Interventions: Device: SCD, Device: GCS, Drug: LMWH | Arm Label: Control group (GCS + LMWH); Type: ACTIVE_COMPARATOR; Interventions: Device: GCS, Drug: LMWH | Intervention Type: DEVICE; Name: SCD; Assigned to Arm(s): Experimental group (SCD + GCS + LMWH) | Intervention Type: DEVICE; Name: GCS; Assigned to Arm(s): Control group (GCS + LMWH), Experimental group (SCD + GCS + LMWH) | Intervention Type: DRUG; Name: LMWH; Assigned to Arm(s): Control group (GCS + LMWH), Experimental group (SCD + GCS + LMWH)
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (BAY59-7939) | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban (BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Arm 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Placebo Controlled Double Blind Crossover Trial of Metformin for Brain Repair in Children with Cranial-Spinal Radiation for Medulloblastoma
Brief Summary: A placebo controlled double blind crossover trial of metformin in 30 children treated with radiation for medulloblastoma - the most common malignant brain tumour. The investigators used tests of thinking and learning and brain imaging techniques to examine whether metformin can enhance cognition or promote brain repair following radiation-induced brain injury.


Options:
A: Arm Label: Delayed exercise control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise
B: Arm Label: Whole Brain Radiation Therapy; Type: EXPERIMENTAL; Interventions: Procedure: Whole Brain Radiation Therapy, Behavioral: Questionnaire | Arm Label: Observation; Type: OTHER; Interventions: Other: Observation, Behavioral: Questionnaire | Intervention Type: PROCEDURE; Name: Whole Brain Radiation Therapy; Assigned to Arm(s): Whole Brain Radiation Therapy | Intervention Type: OTHER; Name: Observation; Assigned to Arm(s): Observation | Intervention Type: BEHAVIORAL; Name: Questionnaire; Assigned to Arm(s): Observation, Whole Brain Radiation Therapy
C: Arm Label: Group A (Crossover Group 1); Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Placebo | Arm Label: Group B (Crossover Group 2); Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Group A (Crossover Group 1), Group B (Crossover Group 2) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group A (Crossover Group 1), Group B (Crossover Group 2)
D: Arm Label: Radiotherapy group; Type: N/A; Interventions: Radiation: Cognitive testing | Arm Label: No radiotherapy group; Type: N/A; Interventions: Radiation: Cognitive testing | Intervention Type: RADIATION; Name: Cognitive testing; Assigned to Arm(s): No radiotherapy group, Radiotherapy group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RCT for the Treatment of Hemodialysis Catheter-Related Bacteremia
Brief Summary: Patients who undergo hemodialysis via a tunneled catheter often develop bloodstream infections that arise from the catheter. There are several management options for treatment of such an infection, though the best option is not clearly delineated. Standard of care options include exchanging the catheter for a new one over a guide-wire and instilling a high concentration of an antibiotic directly into the catheter lumen. The investigators are planning to treat hemodialysis catheter bloodstream infections by one of two strategies: 1. Use of a novel antibiotic lock solution Or 2. Changing out the infected catheter for a new one. Both these options have comparable cure rates as shown in the medical literature. After obtaining informed consent, patients will be randomized to either treatment arm and will continue to receive all other standard medical care.

Specific Aim: To conduct a randomized clinical trial to demonstrate that the use of a novel antibiotic lock solution (consisting of N-acetylcysteine, tigecycline and heparin) is non-inferior to guide-wire exchange in the treatment of hemodialysis catheter-related bacteremia.


Options:
A: Arm Label: Antibiotic Lock Solution; Type: EXPERIMENTAL; Interventions: Drug: tigecycline, N-acetylcysteine, heparin combination | Arm Label: Guide-wire Exchange; Type: ACTIVE_COMPARATOR; Interventions: Device: guide-wire exchange | Intervention Type: DRUG; Name: tigecycline, N-acetylcysteine, heparin combination; Assigned to Arm(s): Antibiotic Lock Solution | Intervention Type: DEVICE; Name: guide-wire exchange; Assigned to Arm(s): Guide-wire Exchange
B: Arm Label: ethanol; Type: EXPERIMENTAL; Interventions: Other: Ethanol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Ethanol | Intervention Type: OTHER; Name: Ethanol; Assigned to Arm(s): ethanol, placebo
C: Arm Label: ClearGuard HD end cap; Type: ACTIVE_COMPARATOR; Interventions: Device: ClearGuard HD end cap | Arm Label: Standard hemodialysis end cap; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: ClearGuard HD end cap; Assigned to Arm(s): ClearGuard HD end cap
D: Arm Label: group A; Type: ACTIVE_COMPARATOR; Interventions: Device: catheter replacement | Arm Label: group B; Type: ACTIVE_COMPARATOR; Interventions: Device: catheter replacement | Intervention Type: DEVICE; Name: catheter replacement; Assigned to Arm(s): group A, group B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias
Brief Summary: This research is being done so that we can look at the safety and efficacy of deferiprone in people with sickle cell disease or other anemias. Deferiprone is a drug that removes iron from the body. We will be comparing deferiprone with deferoxamine, another drug that removes iron from the body.


Options:
A: Arm Label: Deferasirox dispersible tablet (DFX-DT); Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferasirox dispersible tablet | Arm Label: Deferasirox film-coated tablet (DFX-FCT); Type: EXPERIMENTAL; Interventions: Drug: Defearisox film-coated tablet | Intervention Type: DRUG; Name: Deferasirox dispersible tablet; Assigned to Arm(s): Deferasirox dispersible tablet (DFX-DT) | Intervention Type: DRUG; Name: Defearisox film-coated tablet; Assigned to Arm(s): Deferasirox film-coated tablet (DFX-FCT)
B: Arm Label: Deferiprone; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone | Arm Label: Deferoxamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferoxamine | Intervention Type: DRUG; Name: Deferiprone; Assigned to Arm(s): Deferiprone | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Deferoxamine
C: Arm Label: ICL670; Type: EXPERIMENTAL; Interventions: Drug: ICL670 | Arm Label: Deferoxamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: deferoxamine | Intervention Type: DRUG; Name: ICL670; Assigned to Arm(s): ICL670 | Intervention Type: DRUG; Name: deferoxamine; Assigned to Arm(s): Deferoxamine
D: Arm Label: arm 1 iron chelation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferiprone | Arm Label: arm 2 blood transfusion; Type: PLACEBO_COMPARATOR; Interventions: Drug: Deferiprone | Intervention Type: DRUG; Name: Deferiprone; Assigned to Arm(s): arm 1 iron chelation, arm 2 blood transfusion

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Role of Immune-pineal Axis in Fibromyalgia: Noradrenergic Modulation and Chronotherapeutic Aspects
Brief Summary: Fibromyalgia is a common condition in clinical medical practice, characterized by diffuse musculoskeletal pain. Sleep disorders, chronic fatigue, depression, intestinal disorders and headache are also commonly associated with the syndrome .

Although the etiology of this syndrome is not well defined yet, it means involve multiple mechanisms, including low levels of serotonin, increased substance P in cerebrospinal fluid and altered circadian variation in sympathetic - parasympathetic balance, consistent with changes in sympathetic hyperactivity at night .

The immune - pineal system, formed by the integration of the adrenergic and immune systems pineal gland, appears to be involved in the genesis of the dysfunctions found in fibromyalgia. Melatonin is secreted by the pineal gland and has promoter activity of sleep. Studies show that melatonin and its precursors , serotonin and tryptophan are reduced in patients with fibromyalgia.

The present study aims to evaluate the relationship of immune - pineal system in the process of fibromyalgia , since dysfunction of this axis appears to govern the cascading events that participate in the pathophysiological process of this disease.


Options:
A: Arm Label: Melatonin and Placebo; Type: EXPERIMENTAL; Interventions: Drug: Melatonin and Placebo | Arm Label: Amitriptyline and placebo; Type: EXPERIMENTAL; Interventions: Drug: Amitriptyline and Placebo | Arm Label: Melatonin and Amitriptylin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melatonin and Amitriptylin | Intervention Type: DRUG; Name: Melatonin and Placebo; Assigned to Arm(s): Melatonin and Placebo | Intervention Type: DRUG; Name: Amitriptyline and Placebo; Assigned to Arm(s): Amitriptyline and placebo | Intervention Type: DRUG; Name: Melatonin and Amitriptylin; Assigned to Arm(s): Melatonin and Amitriptylin
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran hydrochloride | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran hydrochloride; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Placebo | Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin, Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Duloxetine, Pregabalin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Role of Immune-pineal Axis in Fibromyalgia: Noradrenergic Modulation and Chronotherapeutic Aspects
Brief Summary: Fibromyalgia is a common condition in clinical medical practice, characterized by diffuse musculoskeletal pain. Sleep disorders, chronic fatigue, depression, intestinal disorders and headache are also commonly associated with the syndrome .

Although the etiology of this syndrome is not well defined yet, it means involve multiple mechanisms, including low levels of serotonin, increased substance P in cerebrospinal fluid and altered circadian variation in sympathetic - parasympathetic balance, consistent with changes in sympathetic hyperactivity at night .

The immune - pineal system, formed by the integration of the adrenergic and immune systems pineal gland, appears to be involved in the genesis of the dysfunctions found in fibromyalgia. Melatonin is secreted by the pineal gland and has promoter activity of sleep. Studies show that melatonin and its precursors , serotonin and tryptophan are reduced in patients with fibromyalgia.

The present study aims to evaluate the relationship of immune - pineal system in the process of fibromyalgia , since dysfunction of this axis appears to govern the cascading events that participate in the pathophysiological process of this disease.


Options:
A: Arm Label: Saizen®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Saizen® | Arm Label: Placebo + Saizen®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo and Saizen® | Intervention Type: DRUG; Name: Saizen®; Assigned to Arm(s): Saizen® | Intervention Type: DRUG; Name: Placebo and Saizen®; Assigned to Arm(s): Placebo + Saizen®
B: Arm Label: one arm study; Type: EXPERIMENTAL; Interventions: Drug: trazodone, pregabalin | Intervention Type: DRUG; Name: trazodone, pregabalin; Assigned to Arm(s): one arm study
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 4
D: Arm Label: Melatonin and Placebo; Type: EXPERIMENTAL; Interventions: Drug: Melatonin and Placebo | Arm Label: Amitriptyline and placebo; Type: EXPERIMENTAL; Interventions: Drug: Amitriptyline and Placebo | Arm Label: Melatonin and Amitriptylin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melatonin and Amitriptylin | Intervention Type: DRUG; Name: Melatonin and Placebo; Assigned to Arm(s): Melatonin and Placebo | Intervention Type: DRUG; Name: Amitriptyline and Placebo; Assigned to Arm(s): Amitriptyline and placebo | Intervention Type: DRUG; Name: Melatonin and Amitriptylin; Assigned to Arm(s): Melatonin and Amitriptylin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International, Multi-centre, Randomized Controlled Trial to Assess Transfusion Thresholds in Patients Undergoing Cardiac Surgery
Brief Summary: TRICS-III is an international, multi-centre, open-label randomized controlled trial of two commonly used transfusion strategies in high risk patients having cardiac surgery using a non-inferiority trial design.


Options:
A: Arm Label: Liberal blood transfusion; Type: ACTIVE_COMPARATOR; Interventions: Biological: SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion | Arm Label: Restrictive blood transfusion; Type: ACTIVE_COMPARATOR; Interventions: Biological: SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion | Intervention Type: BIOLOGICAL; Name: SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion; Assigned to Arm(s): Liberal blood transfusion | Intervention Type: BIOLOGICAL; Name: SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion; Assigned to Arm(s): Restrictive blood transfusion
B: Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Restrictive Transfusion Strategy | Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Liberal transfusion strategy | Intervention Type: OTHER; Name: Restrictive Transfusion Strategy; Assigned to Arm(s): Restrictive Transfusion Strategy | Intervention Type: OTHER; Name: Liberal transfusion strategy; Assigned to Arm(s): Liberal Transfusion Strategy
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Sangvia® System | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Sangvia® System; Assigned to Arm(s): 1
D: Arm Label: Restrictive transfusion strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Restrictive Transfusion Strategy | Arm Label: Liberal transfusion strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Liberal transfusion strategy | Intervention Type: OTHER; Name: Restrictive Transfusion Strategy; Assigned to Arm(s): Restrictive transfusion strategy | Intervention Type: OTHER; Name: Liberal transfusion strategy; Assigned to Arm(s): Liberal transfusion strategy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An International, Multi-centre, Randomized Controlled Trial to Assess Transfusion Thresholds in Patients Undergoing Cardiac Surgery
Brief Summary: TRICS-III is an international, multi-centre, open-label randomized controlled trial of two commonly used transfusion strategies in high risk patients having cardiac surgery using a non-inferiority trial design.


Options:
A: N/A
B: Arm Label: Restrictive transfusion strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Restrictive Transfusion Strategy | Arm Label: Liberal transfusion strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Liberal transfusion strategy | Intervention Type: OTHER; Name: Restrictive Transfusion Strategy; Assigned to Arm(s): Restrictive transfusion strategy | Intervention Type: OTHER; Name: Liberal transfusion strategy; Assigned to Arm(s): Liberal transfusion strategy
C: Arm Label: Noradrenaline; Type: EXPERIMENTAL; Interventions: Other: noradrenaline | Arm Label: Ephedrine chorhydrate; Type: EXPERIMENTAL; Interventions: Other: Ephedryne chorydrate | Intervention Type: OTHER; Name: noradrenaline; Assigned to Arm(s): Noradrenaline | Intervention Type: OTHER; Name: Ephedryne chorydrate; Assigned to Arm(s): Ephedrine chorhydrate
D: Arm Label: IV acetaminophen & IV propofol; Type: EXPERIMENTAL; Interventions: Drug: IV acetaminophen & IV propofol | Arm Label: IV acetaminophen & IV dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: IV acetaminophen & IV dexmedetomidine | Arm Label: IV propofol & placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV propofol & placebo | Arm Label: IV dexmedetomidine & placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV dexmedetomidine & placebo | Intervention Type: DRUG; Name: IV acetaminophen & IV propofol; Assigned to Arm(s): IV acetaminophen & IV propofol | Intervention Type: DRUG; Name: IV acetaminophen & IV dexmedetomidine; Assigned to Arm(s): IV acetaminophen & IV dexmedetomidine | Intervention Type: DRUG; Name: IV propofol & placebo; Assigned to Arm(s): IV propofol & placebo | Intervention Type: DRUG; Name: IV dexmedetomidine & placebo; Assigned to Arm(s): IV dexmedetomidine & placebo

Answer: B